CONMED 1Q Performance Better Than Numbers Indicate
The company's orthopedic sales grew in the low single digits for 1Q24, but CONMED faced outsized comparisons and lingering supply...
The company's orthopedic sales grew in the low single digits for 1Q24, but CONMED faced outsized comparisons and lingering supply...
The company grew in the mid-single-digits for 1Q24 but was aided by an unusually robust joint replacement market and one-time...
The company grew in the low double-digits in 2023 but a strategic review revealed Anika's need to focus on the...
The company grew in the mid-teens in 2023 with significant growth across product segments and most regions....
The company turned in a strong fourth quarter to push 2023 orthopedic sales growth into the low-single-digits....
The company grew in the high teens for 2023, driven by its personalized solutions and strength across geographic regions....
The company grew more than 20% in 2023 as it consistently wins share in its Trauma and Deformity business....
The company grew nearly 80% in 2023, with 104% growth in North America on the strength of CERAMENT G sales...
The company grew in the mid-single-digits on a pro forma basis in 2023 and is focused on leveraging its...
The company grew 19% in 2023 despite contending with supply chain constraints and could growth another 20% in 2024....
As a guest member you get access to more articles and webinars every month.
We’ll send a recovery link to your email.
Return to Homepage